A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Latest Information Update: 20 Jun 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Hodgkin's disease; Lymphoma; Malignant melanoma; Neuroblastoma; Solid tumours
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-051
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 12 Sep 2024 According to a Merck & Co media release, company announced that Health Canada has granted approval of KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, as a monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours.
- 10 Jan 2024 Planned End Date changed from 6 May 2025 to 25 Oct 2027.
- 10 Jan 2024 Planned primary completion date changed from 6 May 2025 to 25 Oct 2027.